Provided is a pharmaceutical composition including CADM1 antibodies or antigen-binding fragments thereof. A pharmaceutical composition of the present disclosure for use in the treatment of CADM1-related diseases includes antibodies against CADM1 or antigen-binding fragments thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided is a novel anti-CADM1 antibody or an antigen-binding fragment thereof. An anti-CADM1 antibody or antigen-binding fragment thereof according to the present disclosure binds to an epitope comprising amino acid residues at positions 311, 325 and 326 in cell adhesion molecule 1 (CADM1).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The purpose of the present invention is to provide a plant-derived beta-caryophyllene composition that includes plant-derived beta-caryophyllene and has excellent palatability, and from which a variety of safe products can be obtained, as well as a method for producing the same. In this composition including plant-derived beta-caryophyllene, the plant-derived beta-caryophyllene content is 80 wt% or greater, the eugenol content is 0.0455 wt% or less, and the methyl eugenol content is 0.005 wt% or less.
Although it is desirable to perform imaging after knowing the state of respiration during X-ray testing, such imaging has not been carried out in actual medical sites at present. In addition, since the respiration state and information indicating under what respiration state the testing has been performed have not been stored along with a testing image, it had not been clear how much the respiration state has an effect on the test result during imaging. This X-ray imaging apparatus comprises: an X-ray imaging unit; a millimeter wave radar that irradiates a subject; a display unit that displays an X-ray image obtained by the X-ray imaging unit; and a control unit that displays, on the display unit, an output provided by the millimeter wave radar and a shutter time of the X-ray imaging unit. The X-ray imaging apparatus, by recording the state at the time of imaging instead of suppressing the movement of the body of the subject at the time of imaging, increases reproducibility, eliminates an increase in exposure amount due to re-testing, and provides great additional material when interpreting images.
The brain is slightly off-centered within the skull. In addition, current patient immobilization implements do not provide sufficient position (posture) reproducibility, and aligning a device in order to accurately irradiate a treatment target site in the brain takes a long time. A subject positioning method according to the present invention includes: a step for obtaining a treatment planning image of a subject immobilized relative to a reference plane in order to make a treatment plan for the subject; a step for obtaining a pre-treatment image of the subject immobilized relative to the reference plane immediately prior to treatment of the subject; a step for determining a posture correction value with which the cerebral sulci in the treatment planning image and the cerebral sulci in the pre-treatment image can be made to overlap; and a step for correcting the posture of the subject during treatment on the basis of the posture correction value. In the subject positioning method, the cerebral sulci in the treatment planning image and the pre-treatment image are adjusted to coincide with each other, whereby radiation can be accurately applied to the treatment target site.
Disclosed is a kit for detecting a detection target substance, said kit comprising: a plasmon resonance chip; a first protein that specifically binds to the detection target substance; and a second protein that specifically binds to the detection target substance, wherein the plasmon resonance chip is provided with a substrate, a metallic particle aggregate layer that is formed on the substrate, and a protective layer that covers the metallic particle aggregate layer. Also disclosed is a detection method for a detection target substance which uses said kit.
The purpose is to detect at high sensitivity patients having a high risk of postoperative recurrence based on an expression profile of RNA extracted from platelets collected from cancer patients. To this end, a first expression profile, which is an expression profile of RNA extracted from platelets collected from the postoperative blood of a subject, is compared with cancer sufferer group expression profile, which is a set of expression profiles of RNA extracted from platelets collected from the blood of cancer sufferers belonging to the cancer sufferer group, and a non-cancer sufferer group expression profile, which is a set of expression profiles of RNA extracted from platelets collected from the blood of non-cancer sufferers belonging to the non-cancer sufferer group, and which of the expression profiles the first expression profile is similar to is determined.
McKibben-type pneumatic rubber artificial muscles are known as soft actuators for use in robot devices. However, the McKibben-type pneumatic rubber artificial muscles require a pneumatic supply system, which poses a problem for miniaturization. This artificial muscle includes a cylindrical braided tube that has side surfaces equidistant from a central axis formed by braiding fibers, end securing parts for securing both ends of the braided tube, respectively, a motor that has a drive shaft connected to one of the end securing parts in alignment with the central axis, and a drive control part for driving the motor, the artificial muscle being lightweight, not bulky, and can be suitably used in a wearable environment.
F03G 7/00 - Mechanical-power-producing mechanisms, not otherwise provided for or using energy sources not otherwise provided for
B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewingSafety devices combined with or specially adapted for use in connection with manipulators
F15B 15/10 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type
The present invention addresses the problem of providing: a novel compound; and a use of the compound. The features of the present invention for solving the problem are as follows. 1. A compound represented by chemical formula (1). 2. A compound represented by chemical formula (2). 3. A transepidermal water loss reducing agent containing the compound mentioned in 1 or 2 as an active ingredient. 4. A moisturizing agent containing the compound mentioned in 1 or 2 as an active ingredient. 5. An agent for promoting the production of interleukin-6 in dendritic cells, which contains the compound mentioned in 1 or 2 as an active ingredient. 6. An immunostimulant containing the compound mentioned in 1 or 2 as an active ingredient. 7. A method for producing the compound mentioned in 1 or 2, the method being characterized by including a step for isolating the compound from an extract from rice bran.
C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
A23G 3/36 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition
A23G 4/06 - Chewing gum characterised by the composition
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Provided is a production method for producing a novel fertilizer (e.g., liquid fertilizer) containing a bone tissue degradation product. A production method for producing a fertilizer containing phosphoric acid in accordance with the present disclosure includes at least one of: a step 1 (S7) of producing a fertilizer from a bone solubilization liquid A which has been obtained by treating bone tissue with a solution containing both an acid and a protease; a step 2 (S2) of producing a fertilizer from an acid extract which has been obtained by treating bone tissue with an acid; and a step 3 (S5) of producing a fertilizer from a protease treatment liquid which has been obtained by treating, with a protease, bone tissue which has been treated with an acid.
C05F 1/00 - Fertilisers made from animal corpses, or parts thereof
C01B 25/22 - Preparation by reacting phosphate containing material with an acid, e.g. wet process
C05B 11/06 - Fertilisers produced by wet-treating or leaching raw materials either with acids in such amounts and concentrations as to yield solutions followed by neutralisation, or with alkaline lyes using mineral acid using nitric acid (nitrophosphates)
C05B 11/08 - Fertilisers produced by wet-treating or leaching raw materials either with acids in such amounts and concentrations as to yield solutions followed by neutralisation, or with alkaline lyes using mineral acid using sulfuric acid
C05B 11/12 - Fertilisers produced by wet-treating or leaching raw materials either with acids in such amounts and concentrations as to yield solutions followed by neutralisation, or with alkaline lyes using mineral acid using aqueous hydrochloric acid
C05B 17/00 - Other phosphatic fertilisers, e.g. soft rock phosphates, bone meal
C05F 17/20 - Preparation of fertilisers characterised by biological or biochemical treatment steps, e.g. composting or fermentation using specific microorganisms or substances, e.g. enzymes, for activating or stimulating the treatment
11.
FISH, METHOD FOR PRODUCING FISH, AND METHOD FOR PRODUCING FISH EXHIBITING ACCELERATED MATURATION
Provided is a fish in which accumulation of inosinic acid is enhanced or accelerated during ripening. In a fish of the present disclosure, the function of the ecto-5′-nucleotidase (nt5e) gene is lost.
Provided is a novel method for producing phosphoric acid. A production method for producing phosphoric acid in accordance with the present disclosure includes: a step (a) of obtaining an acid extract by treating bone tissue with an acid; a step (b) of obtaining a calcium phosphate precipitate by adding a base to the acid extract which has been obtained; a step (c) of obtaining a calcium phosphate solution by adding an acid to the calcium phosphate precipitate which has been obtained; and a step (d) of removing precipitated calcium by adding, to the calcium phosphate solution which has been obtained, at least one selected from the group consisting of sulfate, carbonate, and hydrogen carbonate.
Provided is a new method for producing phosphoric acid. A method for producing phosphoric acid according to the present disclosure comprises the following steps. Step S20: A step for treating, with an acid, a raw material containing calcium phosphate to obtain an acid extracted solution. Step S30: A step for mixing the obtained acid extracted solution with a base to obtain a calcium phosphate precipitate. Step S40: A step for mixing the obtained calcium phosphate precipitate with an acid and/or a salt thereof and forming a hardly soluble calcium salt.
Provided is a novel method for producing a calcium salt. A method for producing a calcium salt according to one embodiment of the present disclosure has the following steps. Step S20: A step for acid-treating a raw material containing calcium phosphate to obtain an acid extract. Step S30: A step for mixing the resulting acid extract with a base to obtain a calcium phosphate precipitate. Step S40: A step for mixing the resulting calcium phosphate precipitate with an acid and/or a salt thereof and forming a calcium salt.
NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY (Japan)
KINKI UNIVERSITY (Japan)
Inventor
Hosokawa Yoichiroh
Fujii Mikiya
Onishi Risa
Tsuri Yuka
Yasukuni Ryohei
Ito Akihiko
Wakasa Tomoko
Abstract
Provided is a method for using a sample containing cells collected from a patient to discriminate, with high sensitivity and high accuracy, normal cells and abnormal cells contained in the sample. A sample containing cells collected from a patient is irradiated with electromagnetic waves, an electromagnetic wave scattering spectrum from the cells in the sample is measured, and normal cells and abnormal cells are discriminated on the basis of the characteristics of the electromagnetic wave scattering spectrum. The discrimination uses a trained model in which the electromagnetic wave scattering spectra of normal cells and abnormal cells are trained. The sample may be a living cell, or may be a sample that is immobilized by an alcohol or formalin and dyed. The electromagnetic wave scattering spectrum may use either or both of a scattering spectrum obtained through Rayleigh scattering and a scattering spectrum obtained through Mie scattering.
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
G01N 33/483 - Physical analysis of biological material
Provided is a serum-free medium that is composed of a fewer number of constituent components and is less expensive. The serum-free medium comprises Dulbecco's modified Eagle's medium (DMEM), albumin (BSA), and insulin-transferrin-selenium-ethanolamine (ITS-X). The serum-free medium is suitable for the culturing of mouse ES cells that are naïve pluripotent stem cells, and bears comparison with the most superior medium on the market.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
17.
DETERMINATION METHOD FOR A PSYCHIATRIC DISORDER, PROGRAM, DETERMINATION DEVICE FOR A PSYCHIATRIC DISORDER, AND DETERMINATION SYSTEM FOR A PSYCHIATRIC DISORDER
A determination method for a psychiatric disorder includes: acquiring a first reference value, a second reference value, a first comparison value, and a second comparison value, the first reference value being a heart rate variability index of a healthy person under a first sound stimulus environment, the second reference value being a heart rate variability index of the healthy person under a second sound stimulus environment different from the first sound stimulus environment, the first comparison value being a heart rate variability index of a user under the first sound stimulus environment, the second comparison value being a heart rate variability index of the user under the second sound stimulus environment; and executing comparison processing among the first reference value, the second reference value, the first comparison value, and the second comparison value to determine a possibility that the user has a psychiatric disorder.
In the treatment of cancer, although a molecular targeting agent is highly effective, the survival rate in advanced cancer accompanied by metastasis has not been improved. Therefore, it is an important problem to develop an antitumor drug that is effective against metastatic cancer. This anticancer agent containing a squeezed tea fruit residue extract as an active ingredient is capable of suppressing the proliferation of cancer cells, capable of suppressing migration of cells, and capable of effectively suppressing cancer progression.
It has been reported that acyldepsipeptides (ADEPs) disrupt intracellular protein degradation system complexes so as to exhibit strong antibacterial activities against various pathogenic bacteria including drug-resistant bacteria. In practice, however, it is hard to say that the antibacterial activities are sufficient. It has been confirmed that various cyclic peptide compounds represented by formula (1) according to the present invention exhibit extremely high antibacterial activities compared with ADEP1 and the like.
An optical fiber output light source device includes an optical path that is obtained by joining a polarization maintaining amplifying optical fiber to a polarization maintaining dispersion compensating fiber, a single-polarization reflective polarizing beam splitter that is joined to one end of the optical path, a 90° polarization-rotating reflector that is joined to the other end of the optical path, a multiplexer that is inserted in the optical path, and a pumping light source that is joined to the multiplexer. An axis roll connection portion is provided in which a polarization axis of light returned from the single-polarization reflective polarizing beam splitter to the optical path is connected to a polarization maintaining axis of the optical path with a twisting angle therebetween at a predetermined angle.
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
G02B 27/28 - Optical systems or apparatus not provided for by any of the groups , for polarising
G02F 1/383 - Non-linear optics for second-harmonic generation in an optical waveguide structure of the optical fibre type
H01S 3/108 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity using non-linear optical devices, e.g. exhibiting Brillouin or Raman scattering
Freedom from designated hazardous substances, etc., and good writing properties were demanded of skin markers for making a mark on human skin. This ink for a skin marker that comprises water, a film-forming agent made of a polymer emulsion having a Tg of -70 to 40°C, and a colorant, the materials other than water being only materials listed in the Japanese Standards of Quasi-drug Ingredients 2021, is a water-based composition. Starting with the polymer emulsion used as a film-forming agent, the materials other than water in the ink are made of only materials listed in the Japanese Standards of Quasi-drug Ingredients 2021; therefore, there are no effects on the human body even when used directly on the skin. In addition, a new pen tip can always be used in a writing instrument in which a pen tip impregnated with this ink for a skin marker is covered by a body and a tip cover with an unopened indication means, thereby contributing to infection prevention.
A method of treating short tear breakup time-type dry eye, including a step of administering, to a mammal including a human, (i) a copolymer (P) having three kinds of different constituent units represented by formulae (1a) to (1c) and a weight-average molecular weight of from 5,000 to 2,000,000, wherein a molar ratio among the constituent units [(1a)/(1b)/(1c)] in the copolymer (P) is 100/from 10 to 400/from 2 to 50, or (ii) a composition containing the copolymer (P) at a concentration of from 0.001 w/v % to 1.0 w/v %:
A method of treating short tear breakup time-type dry eye, including a step of administering, to a mammal including a human, (i) a copolymer (P) having three kinds of different constituent units represented by formulae (1a) to (1c) and a weight-average molecular weight of from 5,000 to 2,000,000, wherein a molar ratio among the constituent units [(1a)/(1b)/(1c)] in the copolymer (P) is 100/from 10 to 400/from 2 to 50, or (ii) a composition containing the copolymer (P) at a concentration of from 0.001 w/v % to 1.0 w/v %:
A method of treating short tear breakup time-type dry eye, including a step of administering, to a mammal including a human, (i) a copolymer (P) having three kinds of different constituent units represented by formulae (1a) to (1c) and a weight-average molecular weight of from 5,000 to 2,000,000, wherein a molar ratio among the constituent units [(1a)/(1b)/(1c)] in the copolymer (P) is 100/from 10 to 400/from 2 to 50, or (ii) a composition containing the copolymer (P) at a concentration of from 0.001 w/v % to 1.0 w/v %:
wherein R1 to R6 are as defined herein.
A skeletal structure for an artificial pinna includes a base portion formed in a flat shape with a fibrous structural body using a bioabsorbable material, and a helix portion and an antihelix portion disposed on the front surface of the base portion. In the skeletal structure, the base portion is provided with a two-dimensional elastic structure, and the helix portion and the antihelix portion are provided with a three-dimensional fiber structure formed with the fibrous structural bodies. Thus, a flexible skeletal structure can be provided.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound of formula (I):
The present invention provides a compound of formula (I):
wherein R1, R2, R3, R4, k, l, m and n are as defined in the specification,
or a pharmaceutically acceptable salt thereof with the effect of inhibiting T-type calcium channels and a medicament useful for the treatment of a disease associated with the activation of T-type calcium channels.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
HAGIHARA FARM PRODUCTION INSTITUTE CO.,LTD. (Japan)
KINKI UNIVERSITY (Japan)
Inventor
Kitayama Takashi
Kashiwazaki Gengo
Hashizume Toshiharu
Abstract
It is known that phytol contained in watermelon sprouts has a cancer cell growth inhibiting effect. However, there is a problem that the amount to be ingested for exerting a cancer cell growth inhibiting effect is large. A cancer cell growth inhibiting composition containing at least one component selected from a compound having a structure represented by formula (123) and pharmaceutically acceptable salts thereof as an active ingredient has a higher cancer cell growth inhibiting effect and a lower normal cell growth inhibiting effect than those of phytol and therefore can be used as an anticancer agent having excellent selectivity to cancer cells. R represents a C1-C3 alkyl group.
The purpose of the present invention is to produce a polyamine in the intestines using an oral agent. An enteral polyamine production agent according to the present invention comprises: a bean-derived digestion-resistant peptide comprising a protein component comprising a bean protein material and a degradation residue obtained by the degradation with a degrading enzyme; and a lactic acid bacterium capable of degrading agmatine into putrescine.
HAGIHARA FARM PRODUCTION INSTITUTE CO., LTD. (Japan)
KINKI UNIVERSITY (Japan)
Inventor
Kitayama, Takashi
Kashiwazaki, Gengo
Ashida, Kazuya
Hashizume, Toshiharu
Abstract
Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell.
Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell.
A cancer cell growth-inhibiting composition including a substance having structures represented by formulas (1) to (6) has a higher antiproliferative effect on cancer cell than phytol by order of one or more magnitudes. Further, it is expected that these substances do not affect normal cells similarly to phytol. Thus, they are expected to provide an anticancer drug with less side effects.
Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell.
A cancer cell growth-inhibiting composition including a substance having structures represented by formulas (1) to (6) has a higher antiproliferative effect on cancer cell than phytol by order of one or more magnitudes. Further, it is expected that these substances do not affect normal cells similarly to phytol. Thus, they are expected to provide an anticancer drug with less side effects.
According to one embodiment, a mammography apparatus includes processing circuitry. The processing circuitry is configured to acquire, as information on preliminary X-ray imaging for a breast of a subject, first information including at least one of an imaging condition, breast state information indicating a state of the breast, and/or information on the subject. The processing circuitry is configured to calculate an index for the breast based on the first information.
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
A61B 6/04 - Positioning of patientsTiltable beds or the like
29.
D-LUCIFERIN, D-LUCIFERIN DERIVATIVE, PRECURSOR OF THESE COMPOUNDS AND METHOD FOR PRODUCING THESE COMPOUNDS
To establish an unprecedented novel method for producing D-luciferin and a D-luciferin derivative without using expensive 2-cyano-6-hydroxybenzothiazole that is obtained by a multi-stage production process. In the method for producing D-luciferin and a D-luciferin derivative, the above object is achieved via a novel substituted diaminodithioether represented by the following formula (1):
To establish an unprecedented novel method for producing D-luciferin and a D-luciferin derivative without using expensive 2-cyano-6-hydroxybenzothiazole that is obtained by a multi-stage production process. In the method for producing D-luciferin and a D-luciferin derivative, the above object is achieved via a novel substituted diaminodithioether represented by the following formula (1):
To establish an unprecedented novel method for producing D-luciferin and a D-luciferin derivative without using expensive 2-cyano-6-hydroxybenzothiazole that is obtained by a multi-stage production process. In the method for producing D-luciferin and a D-luciferin derivative, the above object is achieved via a novel substituted diaminodithioether represented by the following formula (1):
wherein X is H, OCH3 or OH; and Y, Z and W are H or monovalent organic groups, which serves as a precursor.
C07C 323/58 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
C07C 319/20 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
30.
EXAMINATION METHOD FOR IMMUNE-RELATED ADVERSE EVENT ENTERITIS
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
[Problem]
[Problem]
COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death.
[Problem]
COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death.
[Solution to Problem]
[Problem]
COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death.
[Solution to Problem]
Compounds represented by formulas (1) to (4) are effective when taken orally and can be expressed in smaller amounts than mangiferin.
[Problem]
COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death.
[Solution to Problem]
Compounds represented by formulas (1) to (4) are effective when taken orally and can be expressed in smaller amounts than mangiferin.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
This bolus, which is for radiation therapy, can be deformed to match the shape of a human body surface, and has little deformation during therapy. The bolus forming material is a rubber composition containing ethylene-propylene rubber and a temperature-sensitive material. The bolus forming material has a JIS type A hardness of 20 or higher at 30° C., and thus is not susceptible to deformation. The bolus forming material has a JIS type E hardness of 10 to 60 at 70° C., and thus easily deforms. The bolus forming material shifts the peak of the percentage depth dose for electron beams and X-rays in the beam source direction at 0.8 to 1.2 times the thickness thereof. Therefore, the bolus forming material has dose characteristics in the depth direction that are substantially the same as a human body. After a sheet of the bolus forming material is heated to around 70° C., the sheet deforms.
There are no drugs or food medicines that can prevent or ameliorate, among side effects caused by drugs, particularly peripheral neuropathy that is caused by anticancer drugs such as oxaliplatin.
There are no drugs or food medicines that can prevent or ameliorate, among side effects caused by drugs, particularly peripheral neuropathy that is caused by anticancer drugs such as oxaliplatin.
An agent for preventing or ameliorating peripheral neuropathy including at least one selected from xylitol, L-talitol, and D-threitol as an active ingredient can ameliorate tingling limbs, limb pain, decreased deep tendon reflexes, muscle weakness, allodynia, hyperalgesia, hand fine motor skill disability, gait disturbance, stumbling, falling, flexion impairment (difficulty or inability to sit on one's knees, cross-legged, sideways, in a chair, etc.), limb paralysis, or the like, induced by drugs such as anticancer drugs or diabetes.
An easy-assembly bed includes a top plate, and a leg portion having a plurality of leg members that are linked using notched joints. The top plate is constituted of a bonded material, which includes a plate-shaped foam plate formed with a foam body, and a front board member and a rear board member having an identical shape to the foam plate and that are bonded to the rear surface and the front surface of the foam plate, respectively, and a top plate molded resin portion overing the cut ends of the bonded material with a molded resin; and the leg members are each constituted of a grooved bonded material, which includes a plate-shaped grooved foam plate having locking grooves and formed with a foam body, and a grooved front board member and a grooved rear board member on the front surface and the rear surface of the grooved foam plate.
Provided is a novel antibody which may be used for the treatment of SARS-CoV-2. An antibody or an antigen-binding fragment thereof according to the present disclosure is an anti-CADM1 antibody or an antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of (Ca) and (Cb): (Ca) an antibody comprising the amino acid sequences of a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 represented by SEQ ID NOs:1, 2 and 3, respectively, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 represented by SEQ ID NOs:4, 5 and 6, respectively; and (Cb) a variant of (a) antibody including some of substitution, insertion, addition, or deletion in the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and/or the light chain CDR3.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
39.
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AORTIC ANEURYSM, AND PROCESSED FOOD
An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.
Antibody preparations for treating allergic diseases have been proposed. However, the route of administration of the antibody preparations is limited to an intravenous route, which imposes a burden on patients. Furthermore, novel drugs that inhibit kinases such as NIK are still needed for the development of effective pharmaceuticals and the like for treating allergic diseases. At least one compound selected from mangiferin 8a having a xanthone backbone (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthydrol (formula (5)), α-mangostin (formula (6)) and γ-mangostin (formula (7)) can ameliorate allergic diseases and can exhibit the effect thereof through oral ingestion.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61P 11/00 - Drugs for disorders of the respiratory system
Provided are fish in which accumulation of inosinic acid is enhanced or accelerated during maturation. The fish of the present disclosure have loss of function of the ecto-5'-nucleotidase (nt5e) gene.
Antibody preparations for treating autoimmune-type diseases such as autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved have been proposed, but the administration route thereof has been limited to intravenous administration, which puts a burden on patients. Furthermore, novel medicines that inhibit kinases such as NIK are constantly needed for the development of effective drugs for treating autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved. At least one compound selected from among yk-7 (formula (1)), yk-8-1, yk-8-3, M7, M9, M11, M12, M14, M15, M16, M18, and M19 having a xanthone skeleton can ameliorate autoimmune-type diseases and is capable of exhibiting an effect when taken orally.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 43/00 - Drugs for specific purposes, not provided for in groups
43.
COMPOSITION FOR TREATING VASCULAR DISEASE, COMPOSITION FOR REVENTING VASCULAR DISEASE, COMPOSITION FOR TREATING HYPERTENSION, AND COMPOSITION FOR PREVENTING HYPERTENSION
Provided is a composition for the treatment of vascular disease, for the prevention of vascular disease, for the treatment of hypertension or for the prevention of hypertension, comprising caryophyllene.
A24D 3/06 - Use of materials for tobacco smoke filters
A24D 3/04 - Tobacco smoke filters characterised by their shape or structure
A24D 3/14 - Use of materials for tobacco smoke filters of organic materials as additive
44.
Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease
Provided are an ocular surface drug-retaining agent that enables an excellent improvement in retainability of a medicament on an ocular surface and an eye drop containing the agent. An ocular surface drug-retaining agent containing a copolymer having three different kinds of constituent units at a specific ratio can express an excellent effect of retaining a medicament on an ocular surface (in particular, a corneal surface) to allow the effect or action of the drug to be sustained over a long period of time.
A composition for treating or preventing respiratory diseases, a composition for improving sleep or promoting sleep onset, a composition for reducing fatigue, a composition for improving complexion, a composition for improving skin texture, a composition for treating or preventing periodontal disease, and a composition for controlling halitosis, each composition containing caryophyllene.
In MRI, the current trend is for gantry magnetic fields to become increasingly stronger in order to enhance the detection accuracy. Thus, it is assumed that even objects referred to as non-magnetic, if electroconductive, may receive an unexpected force due to the magnetic field and perform a dangerous movement. This medical instrument for MRI used in an MRI diagnosis room has a leg in which plate-shaped components are placed upright and combined to form a cylindrical space, a column inserted into the cylindrical space, a leg wedge inserted between the column and the cylindrical space in a direction perpendicular to the direction in which the column is inserted into the cylindrical space, and a head that is fixed to the column and that is constituted from a stage plate and a body obtained by combining plate-shaped components in a grid pattern. The leg, the column, the leg wedge, and the head are non-metallic and insulating bodies. The medical instrument for MRI does not exhibit magnetization not only caused by a magnetic field but also caused by an eddy current, and can therefore be used safely in a strong magnetic field.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Provided is a manufacturing method of a novel fertilizer (for example, a liquid fertilizer) containing a decomposed bone tissue. A manufacturing method of a phosphoric acid-containing fertilizer according to one embodiment of the present invention includes at least one of the following step 1 (S7), step 2 (S2) and step 3 (S5). Step 1 (S7): A step for treating a bone tissue with a solution, which contains both an acid and a protease, and manufacturing a fertilizer from the resulting solubilized bone liquid A. Step 2 (S2): A step for treating a bone tissue with an acid and manufacturing a fertilizer from the resulting acid extract. Step 3 (S5): A step for treating an acid-treated bone tissue with a protease and manufacturing a fertilizer from the resulting protease-treated liquid.
Provided is a novel method for producing phosphoric acid. A method for producing phosphoric acid according to one embodiment of the present invention includes the following steps. (a) A step for treating a bone tissue with an acid to obtain an acid extract. (b) A step for adding a base to the obtained acid extract to obtain calcium phosphate thus precipitated. (c) A step for adding an acid to the obtained calcium phosphate precipitate to obtain a calcium phosphate solution. (d) A step for adding, to the obtained calcium phosphate solution, one or more selected from the group consisting of a sulfate, a carbonate and a hydrogencarbonate to remove calcium thus precipitated.
Provided is a novel method for producing a diarylacetylene derivative. An alkyne derivative having aryl substituents at both ends is provided by subjecting a tetrahalogenated ethylene and phenylboronic acid to a cross-coupling reaction and then conducting a treatment with a base.
C07C 5/00 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
C07C 15/54 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part substituted by unsaturated hydrocarbon radicals polycyclic non-condensed containing a group with formula
C07C 25/24 - Halogenated aromatic hydrocarbons with unsaturated side chains
C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
50.
CARYOPHYLLENE-CONTAINING AGENT OR COMPOSITION AND VARIOUS APPLICATIONS THEREOF
Provided are a novel agent or composition and others.
Provided are a novel agent or composition and others.
The agent or composition comprises caryophyllene and is used for at least one selected from the following (purposes) (1) to (3) :
(1) promoting relaxation, prolonging a resting-state time, and/or prolonging a motionless time,
(2) promoting sleep, and
(3) preventing blood pressure elevation.
Provided are a novel agent or composition and others.
The agent or composition comprises caryophyllene and is used for at least one selected from the following (purposes) (1) to (3) :
(1) promoting relaxation, prolonging a resting-state time, and/or prolonging a motionless time,
(2) promoting sleep, and
(3) preventing blood pressure elevation.
The present invention also relates to a method for inhaling β-caryophyllene simultaneously with smoking a tobacco product, characterized in that the tobacco product contains a β-caryophyllene-containing seamless capsule in a tobacco filter, wherein the seamless capsule contains an essential oil containing β-caryophyllene as an active ingredient. The applicants found that pulmonary inhalation of β-caryophyllene by the above method allows β-caryophyllene to be efficiently distributed throughout the body, leading to achievements of relaxing and sleep-inducing effects, etc.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
KINKI UNIVERSITY (Japan)
Inventor
Murakami Takahiro
Mizuno Satoru
Sawai Toru
Ida Tamio
Abstract
As a solid biofuel serving as an alternative or mix-in for coal coke, there is demand for a solid biofuel that has a high combustion ratio and is capable of long-term combustion and of maintaining form during combustion. This solid biofuel is obtained using a manufacturing method including: a first-stage step in which a raw material that has been chipped from a biomass resulting from photosynthesis is subjected to semi-carbonization to obtain a semi-carbonized raw material in which some of the moisture and volatile content of said raw material is released; and a second-stage step in which the semi-carbonized raw material is heated and pressed to obtain a consolidated molded article. Said solid biofuel has a fuel ratio exceeding 0.4 and a density of 1.0 g/cm322 reduction.
A first reference value that is a heart rate variability index of a normal person under a first auditory stimulus environment, a second reference value that is a heart rate variability index of the normal person under a second auditory stimulus environment that is different from the first auditory stimulus environment, a first comparative value that is a heart rate variability index of a user under the first auditory stimulus environment, and a second comparative value that is a heart rate variability index of the user under the second auditory stimulus environment are acquired. Comparison processing is performed among the first reference value, the second reference value, the first comparative value and the second comparative value to determine the possibility that a user has a mental disease.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
53.
NOVEL COMPOUND, AND PROPHYLACTIC OR AMELIORATING AGENT FOR PERIPHERAL NEUROPATHY WHICH COMPRISES SAME
Heretofore, there has been no medicine or food medicament capable of preventing or ameliorating particularly a peripheral neuropathy induced by an anti-cancer agent such as oxaliplatin among adverse side effects induced by medication. Provided is a prophylactic or ameliorating agent for a peripheral neuropathy, which comprises at least one compound selected from the compounds represented by formulae (1) to (3) as an active ingredient. The prophylactic or ameliorating agent can ameliorate numbness in the limbs, pain in the limbs, decreased deep tendon reflex, loss in muscle strength, allodynia, hyperalgesia, dysfunction in skilled movements of fingers, disturbance in gait, stumbling, falling, difficulties in bodily flexion (difficulties or inabilities associated with such postures as sitting on the soles, sitting with the legs crossed, sitting with the legs folded sideways, or sitting on a chair), limb paralysis or the like which are induced by drugs such as anticancer agents or induced by diabetes. [Formula 200] [Formula 201] [Formula 202]
C07C 69/003 - Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
54.
a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITOR
[Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect.
[Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect.
[Solution] A compound (I) contains a compound represented by a structural formula described below as an active ingredient,
[Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect.
[Solution] A compound (I) contains a compound represented by a structural formula described below as an active ingredient,
Conventional broadband light sources have had the problem of being difficult to oscillate or having an unstable oscillation state. This optical fiber output light source device characterized by including: an optical path connecting a polarization-maintaining amplification optical fiber and a polarization-maintaining dispersion compensation optical fiber; a single-polarization reflective polarizing beam splitter connected to one end of the optical path; a 90° polarization rotation reflector connected to the other end of the optical path; a multiplexer inserted in the optical path; and an axial roll joining part that has an excitation light source connected to the multiplexer and connects, at a prescribed angle, the deviation angle of a polarization-maintaining axis of the optical path relative to a polarization axis of light returning to the optical path from the single-polarization reflective polarizing beam splitter. Reflected components can enter the single-polarization reflective polarizing beam splitter, thereby making oscillation easy and making it less likely that the oscillation state will be impacted by external disturbances.
G02F 1/383 - Non-linear optics for second-harmonic generation in an optical waveguide structure of the optical fibre type
H01S 3/108 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity using non-linear optical devices, e.g. exhibiting Brillouin or Raman scattering
56.
SKELETAL STRUCTURE FOR ARTIFICIAL PINNA AND ARTIFICIAL CARTILAGINOUS TISSUE, AND ARTIFICIAL PINNA USING SAME
In the reconstruction of a lost pinna, an implant-type regenerative medicine is performed. In this case, a skeletal structure using a bioabsorbable material has been proposed as a cell scaffold material. However, a skeletal structure that has strength, can be deformed easily, has restoring force, and is flexible has been still expected. Provided is a skeletal structure (1) for an artificial pinna, which is characterized by comprising a planar base part (10) formed from a fibrous structure using a bioabsorbable material and a helix part (30) and an antihelix part (20) both provided on the surface of the base part (10). In the skeletal structure (1), a two-dimensional elastic structure is provided to the base part (10) and a three-dimensional fibrous structure formed from a fibrous structure is provided to each of the helix part (30) and the antihelix part (20). As a result, a flexible skeletal structure can be provided.
The present invention addresses the problem of providing a method for efficiently producing α-tomatine. The method for producing α-tomatine that solves the problem includes a step for mixing at least one tomato plant body selected from the group consisting of tomato leaves, stems, auxiliary buds, immature fruits, and roots with an acidic solution and crushing the tomato plant bodies in the acidic solution to obtain an extract of α-tomatine. The pH of the extract is set at 4.5 or less.
C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically acceptable salt thereof, and a drug that is useful in the treatment of diseases caused by activation of T-type calcium channels.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
To provide a novel T-type calcium channel blocker.
To provide a novel T-type calcium channel blocker.
A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.
To provide a novel T-type calcium channel blocker.
A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.
wherein A represents a phenyl which may have a substituent, a 4-membered to 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, while here, the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to a nitrogen atom of the adjacent cyclic amino by means of a carbon atom constituting these rings;
B represents a phenyl which may have a substituent, a 5-membered or 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, while here, the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to the adjacent cyclopropyl ring by means of a carbon atom constituting these rings;
R1 and R2, which may be identical or different, each represent a hydrogen atom, a halogen atom, or the like;
R3 represents a hydrogen atom, a halogen atom, or the like;
n and m, which may be identical or different, each represent 0 or 1; and p represents 1 or 2.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07F 7/08 - Compounds having one or more C—Si linkages
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
60.
TAMARIND DECOMPOSITION PRODUCT, BUTYRIC ACID-PRODUCING BACTERIA PROPAGATION PROMOTER, COMPOSITION FOR INTESTINAL BUTYRIC ACID PRODUCTION, AND TAMARIND DECOMPOSITION PRODUCT PRODUCTION METHOD
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression.
An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.
HAGIHARA FARM PRODUCTION INSTITUTE CO.,LTD. (Japan)
KINKI UNIVERSITY (Japan)
Inventor
Kitayama Takashi
Kashiwazaki Gengo
Ashida Kazuya
Hashizume Toshiharu
Abstract
The phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. The problem, however, is the amount ingested to inhibit cancer cell growth is large. A cancer cell growth inhibiting composition having a substance having a structure represented by formulas (1) through (6) as the main component has a cancer cell growth inhibiting effect one or more orders of magnitude greater than that of phytol. Like phytol, these substances are expected to have no effect on normal cells. Provision of an anticancer agent with few side effects can therefore be expected.
C07C 323/58 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
C07C 319/14 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
64.
THERAPEUTIC FOR LUNG CANCER THAT HAS ACQUIRED RESISTANCE TO TYPE 1 ANTICANCER DRUGS
The type 1 MET tyrosine kinase inhibitors capmatinib and tepotinib are effective against lung cancer having an MET exon 14 skipping mutation and have been approved as first-line drugs in Japan and the US, but it is expected that resistance to both of these drugs will be acquired. However, there were no prospects for drugs that could be used next. Lung cancer therapeutics having as an active ingredient any compound of formula (1) and formula (2) can overcome resistance to capmatinib and tepotinib and manifest an effect as an inhibitor against lung cancer having an MET exon 14 skipping mutation in which the amino acids 1228 and 1230 of c-MET are mutated to an amino acid other than aspartic acid and tyrosine, respectively.
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
COVID-19 caused by a coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome in a chimeric antigen receptor (CAR)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytotic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu's arteritis and the like cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory failure, multiple organ failure or the like when being increased in severity, and are believed to be one of causes of death. This phenomenon is considered to be caused by cytokine storm. Compounds represented by formulae (1) to (4) exert the effects thereof when administered orally, and can exert the effects thereof in smaller amounts than that of mangiferin. [Formula 105] [Formula 106] [Formula 107] [Formula 108]
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
An object is to provide a cell culture scaffold which makes it possible to recover a cell culture product without being destroyed after cell culturing and a method for producing a cell culture product.
An object is to provide a cell culture scaffold which makes it possible to recover a cell culture product without being destroyed after cell culturing and a method for producing a cell culture product.
The cell culture scaffold according to the present invention includes a substrate having a water-repellent surface and a cell adhesion molecule formed on the water-repellent surface of the substrate. Further, the method for producing a cell culture product according to the present invention includes a step of culturing, using the cell culture scaffold, cells on the surface of the cell adhesion molecule. The cell culture scaffold according to the present invention makes it possible to recover the cells in a spheroid state without causing a damage.
Heretofore, there has been no medicine or food medicament capable of particularly preventing or improving, among side effects caused by medication, peripheral neuropathy caused by anticancer drugs such as oxaliplatin. This agent for preventing or improving peripheral neuropathy contains, as an active ingredient, at least one selected from among xylitol, L-talitol, and D-threitol, and contributes to improving symptoms that are induced by medication such as anticancer drugs or induced by diabetes, and that include numbness in the limbs, pain in the limbs, decreased deep tendon reflex, loss in muscle strength, allodynia, hyperalgesia, dysfunction in skilled movements of fingers, disturbance in gait, stumbling, falling, difficulties in bodily flexion (difficulties or inabilities associated with such postures as sitting on the soles, sitting with the legs crossed, sitting with the legs folded sideways, or sitting on a chair), or limb paralysis.
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
This bolus, which is for radiation therapy, can be deformed to match the shape of a human body surface, and has little deformation during therapy. The bolus forming material is a rubber composition containing ethylene-propylene rubber and a temperature-sensitive material. The bolus forming material has a JIS type A hardness of 20 or higher at 30°C, and thus is not susceptible to deformation. The bolus forming material has a JIS type E hardness of 10 to 60 at 70°C, and thus easily deforms. The bolus forming material shifts the peak of the percentage depth dose for electron beams and X-rays in the ray source direction at 0.8 to 1.2 times the thickness thereof. Therefore, the bolus forming material has dose characteristics in the depth direction that are substantially the same as a human body. After a sheet of the bolus forming material is heated to around 70°C, the sheet deforms so as to match the shape of the surface of a body of a patient. When this sheet is cooled, it is possible to obtain a bolus that closely adheres to the body of the patient. By interposing the bolus between the patient and an irradiation device, it is possible to adjust the dose characteristics in the depth direction.
A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
71.
EASY-ASSEMBLY BED, MULTIPURPOSE TABLE, AND TRANSPORTATION LIGHTWEIGHT BOARD
There are societal demands during times of emergency and the like for a bed that has few components and is easy to assemble, is strong and lightweight, and has excellent heat retaining properties and water resistance, and the present invention proposes a bed with which these requirements can be achieved in a well-balanced manner. An easy-assembly bed (1) includes a top plate (10), and leg portions (30) in which a plurality of leg members (20) are linked using notched joints, wherein: the top plate (10) is configured from a bonded material comprising a plate-shaped foam plate (42) formed from a foam body, and a front board member and a rear board member having the same shape as the foam plate, which are bonded to the rear surface and the front surface of the foam plate (42), and a top plate molded resin portion obtained by covering the cut ends of the bonded material with molded resin; and the leg members (20) are each configured from a grooved bonded material including a plate-shaped grooved foam plate which has latching grooves and which is formed from a foam body, and, on the front surface and the rear surface of the grooved foam plate, a grooved front board member and a grooved rear board member having the same shape as the grooved foam plate, and a leg member molded resin portion obtained by covering the cut ends of the grooved bonded material with molded resin.
An aortic aneurysm does not have many noticeable symptoms, and the risk of rupturing while still unnoticed is high. Further, when rupturing occurs, a patient enters a shock state due to massive bleeding, and the rate of survival is extremely low. Consequently, when an aortic aneurysm is discovered in a medical examination or the like, depending on the stage of progression, it has been necessary to carry out a surgery such as a stent-graft. This pharmaceutical composition for prevention and treatment of an aortic aneurysm, which has a medium chain fatty acid as a main component thereof, has the effect of inhibiting the development and progression of an aortic aneurysm; thus, when an aortic aneurysm is discovered, by continued use of the pharmaceutical composition, it is possible to not just inhibit the progression of the aortic aneurysm, but also to cause regression of the aortic aneurysm, and it is possible to exhibit the effect of improving life prognosis.
Provided are a therapeutic agent for short tear breakup time (TBUT)–type dry eye, which has excellent therapeutic effect on dry eye and high safety, and eye drops containing the therapeutic agent. The present inventors found that a therapeutic agent for short TBUT-type dry eye, said therapeutic agent comprising a copolymer which has three different structural units at a specific ratio and water, is efficacious for treating dry eye, because this therapeutic agent sufficiently moisturizes the corneal surface and retains water thereon so as to induce mucin production on the corneal surface, thereby completing the invention.
Eyedrops for ameliorating retinal circulatory disturbance and disorders associated with retinal nerve blood vessels, which contains fibrate-containing nanoparticles.
COMPOSITION FOR TREATING VASCULAR DISEASE, COMPOSITION FOR PREVENTING VASCULAR DISEASE, COMPOSITION FOR TREATING HYPERTENSION, AND COMPOSITION FOR PREVENTING HYPERTENSION
A composition for treating a vascular disease, for preventing a vascular disease, for treating hypertension or for preventing hypertension, which contains caryophyllene.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HAGIHARA FARM PRODUCTION INSTITUTE CO., LTD. (Japan)
KINKI UNIVERSITY (Japan)
MIE UNIVERSITY (Japan)
Inventor
Hashizume, Toshiharu
Kitayama, Takashi
Kashiwazaki, Gengo
Hirabayashi, Satoru
Utaka, Yoshimi
Taneda, Keigo
Itoh, Tomohiro
Abstract
Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhibition is large.
A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.
C07C 233/09 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
77.
COLLAGEN SOLID, METHOD FOR PRODUCING COLLAGEN SOLID, BIOMATERIAL, AND EX VIVO MATERIAL
The present invention provides a collagen solid having higher strength and density. A collagen solid is used which contains a collagen-cysteine protease degradation product or an atelocollagen-cysteine protease degradation product and has a density of 50 mg/cm3 or more.
This nerve regeneration inducing tube cutting tool (1) comprises: a base member (10); a nerve regeneration inducing tube mounting groove (12) into which a nerve regeneration inducing tube (100) is to be mounted, the groove being provided so as to extend in a first direction and recessed from a surface (15) of the base member (10); and a guide groove (14) that guides the passage of a cutting knife for cutting the nerve regeneration inducing tube (100), the guide groove extending in a second direction orthogonal to the first direction in which the nerve regeneration inducing tube mounting groove (12) extends and traversing the nerve regeneration inducing tube mounting groove (12), a plurality of guide grooves (14) being provided along the first direction. With this nerve regeneration inducing tube cutting tool, the work of cutting the nerve regeneration inducing tube to a prescribed length can easily be accomplished accurately and quickly.
A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor,
n represents 0 or 1.
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
According to a conventional method for determining a resonance frequency, vibration of an implant or the like is caused using light, and the state of the vibration is subjected to frequency analysis. However, the method requires the use of a strong light source, and therefore imposes a lot of burden when used. This installation strength measurement device is characterized by comprising: a vibration-causing light generator for irradiating a measurement object with light having varying intensity; a vibration measuring instrument for measuring at least the vibration intensity of the measurement object between the vibration frequency and vibration intensity of the measurement object; and a controller for obtaining information pertaining to the installation strength of the measurement object by causing the vibration-causing light generator to irradiate the measurement object with the light at a plurality of irradiation cycles, obtaining the amplitude intensity from the vibration measuring instrument at each irradiation cycle, and selecting a vibration frequency providing the highest vibration intensity. The installation strength measurement device is usable without any restriction and imposes least burden on a user, because the installation strength measurement device determines the resonance frequency of a fixed object using weak light.
Provided are a novel agent or composition, etc. The agent or composition contains caryophyllene and is used for at least one (purpose) selected from (1)-(3) below. (1) Promotion of a relaxing effect, prolongation of rest time and/or prolongation of quiescent time. (2) Sleep promotion. (3) Suppression of blood pressure elevation. The present invention also pertains to a method for filling a seamless capsule with an essential oil having β-caryophyllene as an active ingredient and mounting the capsule on a cigarette filter, whereby the β-caryophyllene is inhaled simultaneously with smoking. The applicant discovered that by inhaling β-caryophyllene through the lungs by the above method, β-caryophyllene is efficiently distributed throughout the body, leading to a relaxing effect, a sleep-inducing effect, etc.
No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin.
Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.
To improve the fact that the main components of conventional deodorizing and antimicrobial agents are existing components, the effect and efficacy of which are known to some extent, and do not generate an effect better than predicted. The deodorizing and antimicrobial agent of the present invention has a loquat seed extract including non-volatile fatty acids and at least benzaldehyde and benzoic acid as a main raw material.
A01N 65/34 - Rosaceae [Rose family], e.g. strawberry, hawthorn, plum, cherry, peach, apricot or almond
A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
A61L 9/013 - Deodorant compositions containing animal or plant extracts, or vegetable material
A01N 35/04 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio-analogues thereof, directly attached to an aromatic ring system, e.g. acetophenoneDerivatives thereof, e.g. acetals
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereofDerivatives thereof
[Problem] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect. [Solution] Compound (I) which comprises a compound represented by a structural formula as an active ingredient.
The present invention addresses the problem of providing: a cell culture scaffold from which a cell culture can be recovered without being destroyed after culturing cells; and a method for producing a cell culture. The cell culture scaffold according to the present invention is provided with a base having a water-repellent surface and a cell adhesion molecule formed on the water-repellent surface of the base. In addition, the method for producing a cell culture according to the present invention includes a step for using the cell culture scaffold to culture cells on the surface of the cell adhesion molecule. The cell culture scaffold according to the present invention can allow cells to be recovered in a spheroid shape without being damaged.
Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Aortic aneurysms have few subjective symptoms and carry a high risk of silent rupture. In addition, when rupture occurs, shock appears due to major blood loss and the survival rate is very low. Thus, when discovered by, for example, a checkup, surgery has been necessary, e.g., a stent graft, depending on the state of development. A pharmaceutical composition for aortic aneurysm prophylaxis having medium-chain fatty acids as the main component has a suppressive effect on the occurrence and development of aortic aneurysms, and as a consequence the sustained intake of same can suppress occurrence and development of the aortic aneurysm and exhibit a prognosis-improving effect when an aortic aneurysm is discovered.
A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
89.
USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type calcium channel and that is represented by any one of general formulae (I)-(VI), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of blocking the T-type calcium channel (Cav3.2 channel) and that is represented by any one of general formulae (I)-(VI), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Tsubota, Maho
Toyooka, Naoki
Nishikawa, Hiroyuki
Abstract
A new analgesic has been developed for T-type calcium channels as therapeutic targets.
The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1):
or a pharmaceutically acceptable salt or solvate thereof.
The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.
HAGIHARA FARM PRODUCTION INSTITUTE CO.,LTD. (Japan)
KINKI UNIVERSITY (Japan)
MIE UNIVERSITY (Japan)
Inventor
Hashizume Toshiharu
Kitayama Takashi
Kashiwazaki Gengo
Hirabayashi Satoru
Utaka Yoshimi
Taneda Keigo
Itoh Tomohiro
Abstract
The phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. The problem, however, is the amount ingested to inhibit cancer cell growth is large. A cancer cell growth inhibiting composition having as the main ingredient at least one among compounds having structures represented by formula (1), formula (2), formula (6), formula (7), or formula (8) or pharmaceutically acceptable salts thereof has a higher cancer cell growth inhibiting effect than phytol.
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 233/09 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
93.
HARMFUL SUBSTANCE TREATMENT METHOD AND OZONE GENERATING DEVICE
A treatment method is capable of degrading or sterilizing harmful substances or microorganisms of which the degradation, detoxification, or the like is not easy for ozone gas alone. A harmful substance treatment method is one that makes ozone gas act on harmful substances, microorganisms, or the like in an environment humidified using a surfactant solution. The harmful substances include anticancer drugs. As a surfactant to be used, a non-ionic surfactant, an anionic surfactant, a cationic surfactant, or an amphoteric surfactant can be used.
A62D 3/38 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by oxidationProcesses for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by combustion
94.
NAPHTHOQUINONE COMPOUND HAVING ANTIBACTERIAL AND ANTIVIRAL ACTIVITIES AND PHARMACEUTICAL USE THEREOF
Provided is a naphthoquinone compound that exhibits antibacterial and antiviral activities against various fungi and bacteria. A compound represented by formula (I) [wherein: R11-61-61-6 alkyl-CO] or a pharmaceutically acceptable salt thereof.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
Compounds for ameliorating or treating malignant tumor diseases have been proposed, but many of those cannot be orally taken and have placed a burden on patients. Mangiferin has the effect of ameliorating malignant tumor diseases through oral intake, but the effect is small, and it has been realistically not easy to take mangiferin. Furthermore, a novel or improved form of an existing drug for inhibiting a kinase such as NIK has been constantly needed for development of a more effective medicine and the like for treating malignant tumor diseases. According to the present invention, formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), and formula (7) are effective when being orally taken, and can exhibit the effect in small amounts compared to mangiferin.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
EuglenaEuglenaEuglenaEuglenaEuglena2-8EuglenaEuglenaEuglenaEuglenaEuglena convert all of the accumulated paramylon to wax ester. As a result, the production efficiency of wax ester increases.
C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
C12N 1/12 - Unicellular algaeCulture media therefor
A transfer material for hard tissue regeneration is provided which is useful for adhering a biocompatible ceramic film to a patient's hard tissue such as a tooth. This transfer material for hard tissue regeneration is provided with a temporary support body which has an easily peelable surface that allows easy separation of the biocompatible ceramic film, and a biocompatible ceramic film which is formed on the easily peelable surface of the temporary support body.
A61K 6/831 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
Antibody preparations for improving or treating autoimmune diseases have been proposed, but the route of administration is limited to intravenous, imposing a burden on the patient. Also, mangiferin has an effect for improving autoimmune disease by oral ingestion, but the effect is small and realistic ingestion was not easy. Furthermore, novel drugs that inhibit kinases such as NIK are always needed to develop effective pharmaceuticals and the like for treating autoimmune diseases. At least one compound selected from substances represented by formula (1), norathyriol, 1,3,5,6-tetrahydroxyxanthone, xanthydrol, α-mangosteen, and γ-mangosteen has an effect by oral ingestion, and this effect can be exhibited by a smaller amount than was possible with mangiferin.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
99.
COLLAGEN SOLID, METHOD FOR PRODUCING COLLAGEN SOLID, BIOMATERIAL, AND EX VIVO MATERIAL
NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (Japan)
Inventor
Morimoto, Koichi
Kunii, Saori
Fukase, Naomasa
Kuroda, Ryosuke
Takemori, Toshiyuki
Abstract
Provided is a collagen solid having high strength and density. According to the present invention, there is used a collagen solid including a collagen-cysteine protease degradation product or an atelocollagen-cysteine protease degradation product, the collagen solid having a density of 50 mg/cm3 or higher.
Heretofore, methods for controlling the behavior of fish have not been well-established. Conventionally, fish were gathered with light, as seen for example in traditional squid fishing. However, guiding fish inside a determined space such as a fish tank or culture tank was not effective. This fish behavior control method is characterized by irradiating a repellent color in the region outside of where the fish should be guided to; rather than fish gathering around a light, a restricted region is created with light of a color that repels, making it possible to cause the fish to move in the desired direction.
A01K 63/06 - Arrangements for heating or lighting in, or attached to, receptacles for live fish
A01M 29/10 - Scaring or repelling devices, e.g. bird-scaring apparatus using visual means, e.g. scarecrows, moving elements, specific shapes, patterns or the like using light sources, e.g. lasers or flashing lights
